Table 2.
Changes in tumor microenvironment (TME) before and after developing acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) therapy among patients with non‐small cell lung carcinoma and available paired tissues (N = 7)
| Patient | EGFR | Smoking | Pre | Rebiopsy | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Biopsy site Procedure |
PD‐L1 TPS | CD8+ score | PD‐L2 | TME subtype |
First‐line TKI Best response |
Rebiopsy site Procedure |
T790M | PD‐L1 TPS | CD8+ score | PD‐L2 | TME subtype | Response to osimertinib | |||
| 1 | L858R | No |
Primary lesion TBB |
<1% | 1 | − | Type 2 |
G/E PR |
Dissemination to PL Small resection |
+ | 3% | 2 | + | Type 4 | PR |
| 2 | L858R | No |
Primary lesion TBB |
0% | 2 | − | Type 4 |
G PR |
Primary lesion TBB |
− | 1% | 1 | − | Type 2 | − |
| 3 | Del19 | No |
Primary lesion TBB |
60% | 1 | − | Type 3 |
G/E PR |
Bone metastasis Resection |
+ | 30% | 0 | − | Type 2 | NE |
| 4 | Del19 | Yes |
Lymph node Needle biopsy |
60% | 1 | − | Type 3 |
G PR |
Primary lesion Resection |
− | 100% | 3 | − | Type 1 | − |
| 5 | L858R | No |
Primary lesion CT‐GLB |
0% | 2 | − | Type 4 |
E PR |
Primary lesion CT‐GLB |
+ | 100% | 3 | + | Type 1 | SD |
| 6 | L858R | No |
Primary lesion TBB |
30% | 2 | + | Type 4 |
E PR |
Primary lesion TBB |
+ | 8% | 1 | − | Type 2 | PR |
| 7 | L858R | No |
Primary lesion TBB |
70% | 1 | − | Type 3 |
E PR |
Primary lesion TBB |
− | 20% | 0 | − | Type 2 | − |
CT‐GLB, computed tomography‐guided percutaneous lung biopsy; E, erlotinib; G, gefitinib; NE, not evaluable; PD‐L1/2, programmed cell death‐1 ligand‐1/2; PL, pleura; PR, partial response; SD, stable disease; TBB, transbronchial biopsy; TPS, tumor proportion score.